Edoxaban tosylate monohydrate
Modify Date: 2024-01-02 17:50:18
Edoxaban tosylate monohydrate structure
|
Common Name | Edoxaban tosylate monohydrate | ||
|---|---|---|---|---|
| CAS Number | 1229194-11-9 | Molecular Weight | 738.274 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C31H40ClN7O8S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Edoxaban tosylate monohydrateEdoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke preventionIC50 Value:Target: factor XaEdoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) and/or nonsteroidal anti-inflammatory drugs for concurrent illnesses[1].in vitro: Edoxaban PK was not affected by concomitant low-dose ASA or naproxen, but high-dose ASA increased systemic exposure of edoxaban by approximately 30%. The effects of edoxaban on prothrombin time, activated partial thromboplastin time, international normalized ratio, anti-FXa, and intrinsic FXa activity were not influenced by administration with ASA or naproxen. Inhibition of platelet aggregation by high-dose ASA, low-dose ASA, or naproxen was not affected by edoxaban[1].in vivo: Forty-eight subjects, aged 18 to 45 years, received either edoxaban 60 mg once daily × 7 days (n = 24) or digoxin 0.25 mg twice daily × 2 days and once daily × 5 days (n = 24) and then concomitantly for 7 days. Serial blood and urine samples were collected for digoxin and edoxaban concentrations on days 7 and 14. Serial coagulation assays were measured for edoxaban on days 7 and 14. Edoxaban PK parameters demonstrated mild increases in area under the curve and peak concentrations of 9.5% and 15.6%, respectively[2],Clinical trial: Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans was reported[3]. |
| Name | edoxaban tosylate hydrate |
|---|---|
| Synonym | More Synonyms |
| Description | Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke preventionIC50 Value:Target: factor XaEdoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) and/or nonsteroidal anti-inflammatory drugs for concurrent illnesses[1].in vitro: Edoxaban PK was not affected by concomitant low-dose ASA or naproxen, but high-dose ASA increased systemic exposure of edoxaban by approximately 30%. The effects of edoxaban on prothrombin time, activated partial thromboplastin time, international normalized ratio, anti-FXa, and intrinsic FXa activity were not influenced by administration with ASA or naproxen. Inhibition of platelet aggregation by high-dose ASA, low-dose ASA, or naproxen was not affected by edoxaban[1].in vivo: Forty-eight subjects, aged 18 to 45 years, received either edoxaban 60 mg once daily × 7 days (n = 24) or digoxin 0.25 mg twice daily × 2 days and once daily × 5 days (n = 24) and then concomitantly for 7 days. Serial blood and urine samples were collected for digoxin and edoxaban concentrations on days 7 and 14. Serial coagulation assays were measured for edoxaban on days 7 and 14. Edoxaban PK parameters demonstrated mild increases in area under the curve and peak concentrations of 9.5% and 15.6%, respectively[2],Clinical trial: Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans was reported[3]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C31H40ClN7O8S2 |
|---|---|
| Molecular Weight | 738.274 |
| Exact Mass | 737.206848 |
| PSA | 236.85000 |
| LogP | 4.34050 |
| Storage condition | -20℃ |
| N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide,4-methylbenzenesulfonic acid,hydrate |
| Edoxaban tosylate monohydrate |
| N-(5-Chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-{[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl]ethanediamide 4-methylbenzenesulfonate hydrate (1:1:1) |
| Edoxaban tosilate monohydrate |
| Edoxaban tosilate hydrate (JAN) |
| Edoxaban |
| Lixiana |
| Edoxaban tosilate |
| LIXIANA (TN) |
| CS-1333 |
| Ethanediamide, N-(5-chloro-2-pyridinyl)-N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, 4-methylbenzenesulfonat e, hydrate (1:1:1) |
| Edoxaban Impurity 1 |
| Edoxaban (tosylate monohydrate) |
- Shanghai Jizhi Biochemical Technology Co., Ltd
- China
- Product Name: Edoxaban tosylate monohydrate
- Price: ￥1216.0/25mg ￥2736.0/100mg ￥606.0/10mg ￥406.0/5mg
- Purity: 98.0%
- Stocking Period: 2 Day
- Contact: Liu jia
- DC Chemicals Limited
- China
- Product Name: Edoxaban tosylate monohydrate
- Price: $450.0/100mg $800.0/250mg $1500.0/1g
- Purity: 98.0%
- Stocking Period: 3 Day
- Contact: Tony Cao
- Henan Tianfu Chemical Co., Ltd.
- China
- Product Name: Edoxaban TsOH salt
- Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
- Purity: 99.0%
- Stocking Period: Inquiry
- Contact: Anson
Get all suppliers and price by the below link:
Edoxaban tosylate monohydrate suppliers
Price: ￥312/5mg
Reference only. check more Edoxaban tosylate monohydrate price